About Sienna Durbin, MD
Clinical Interests:
- Inpatient oncology
Treats:
- Adult
Medical Education
- MD, Harvard Medical School
- Residency, Mass General Hospital
- Fellowship, Mass General Brigham Combined Training Program
American Board Certifications
- Internal Medicine, American Board of Internal Medicine
Accepted Insurance Plans
- Aetna
- Beech Street
- Blue Cross Blue Shield
- Blue Cross Blue Shield Medicare
- Cigna
- Commonwealth Care Alliance
- Coventry
- Fallon Health
- Harvard Pilgrim Health Care
- Humana
- Maine Community Health Options
- Mass General Brigham Health Plan
- MassHealth
- Medicaid ME
- Medicaid NH
- Medicaid RI
- Medicaid VT
- Medicare
- Medicare ACO
- Multiplan
- Railroad Medicare
- Senior Whole Health
- TriCare
- Tufts Health Plan
- United Health Care
- Wellpoint
- WellSense
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
Publications
-
Petrillo LA, El-Jawahri A, Nipp RD, Lichtenstein MRL, Durbin SM, Reynolds KL, Greer JA, Temel JS, Gainor JF. Performance status and end-of-life care among adults with non-small cell lung cancer receiving immune checkpoint inhibitors. Cancer. 2020 May 15;126(10):2288-2295. PMID: 32142165, https://doi.org/10.1002/cncr.32782
Durbin SM, Mooradian MJ, Fintelmann FJ, Zubiri L, Chute DF, Kambadakone A, Pisuchpen N, Reynolds KL, Dougan M. Diagnostic utility of CT for suspected immune checkpoint inhibitor enterocolitis. J Immunother Cancer. 2020 Oct;8(2). PMID: 33033184, PMCID: PMC7545618, https://doi.org/e001329
Durbin SM, Zubiri L, Niemierko A, Bardia A, Sullivan RJ, McEwen C, Mulvey TM, Allen IM, Lawrence DP, Cohen JV, Hochberg EP, Ryan DP, Petrillo LA, Reynolds KL. Clinical Outcomes of Patients with Metastatic Cancer Receiving Immune Checkpoint Inhibitors in the Inpatient Setting. Oncologist. 2021 Jan;26(1):49-55. PMID: 33044765, PMCID: PMC7794195, https://doi.org/10.1002/onco.13561
Thompson LL, Katznelson E, Leet DE, Durbin SM, Yoon J, Reynolds KL, Dougan ML, Chen ST. Impact of systemic corticosteroids on survival outcomes in immune checkpoint inhibitor-induced gastroenterocolitis. Eur J Cancer. 2021 Jan;142:143-146. PMID: 33268234, PMCID: PMC8300871, https://doi.org/10.1016/j.ejca.2020.09.022
Molina GE, Zubiri L, Cohen JV, Durbin SM, Petrillo L, Allen IM, Murciano-Goroff YR, Dougan M, Thomas MF, Faje AT, Rengarajan M, Guidon AC, Chen ST, Okin D, Medoff BD, Nasrallah M, Kohler MJ, Schoenfeld SR, Karp Leaf RS, Sise ME, Neilan TG, Zlotoff DA, Farmer JR, Mooradian MJ, Bardia A, Mai M, Sullivan RJ, Semenov YR, Villani AC, Reynolds KL. Temporal trends and outcomes among patients admitted for immune-related adverse events: A Single-Center Retrospective Cohort Study from 2011 to 2018. Oncologist. 2021 Jun;26(6):514-522. PMID: 33655682, PMCID: PMC8176966, https://doi.org/10.1002/onco.13740
Zubiri L, Molina GE, Mooradian MJ, Cohen J, Durbin SM, Petrillo L, Boland GM, Juric D, Dougan M, Thomas MF, Faje AT, Rengarajan M, Guidon AC, Chen ST, Okin D, Medoff BD, Nasrallah M, Kohler MJ, Schoenfeld SR, Karp-Leaf RS, Sise ME, Neilan TG, Zlotoff DA, Farmer JR, Bardia A, Sullivan RJ, Blum SM, Semenov YR, Villani AC, Reynolds KL. Effect of a multidisciplinary Severe Immunotherapy Complications Service on outcomes for patients receiving immune checkpoint inhibitor therapy for cancer. J Immunother Cancer. 2021 Sep;9(9). PMID: 34544895, PMCID: PMC8454442, https://doi.org/e002886